Bristol-Myers Squibb vs Vertex Pharmaceuticals

Bristol-Myers Squibb (BMY), health care, and Vertex Pharmaceuticals (VRTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Vertex Pharmaceuticals is worth $135.1B on the stock market and Bristol-Myers Squibb $124.7B: Vertex Pharmaceuticals is valued at 8% more. Bristol-Myers Squibb trades at 13.5 times earnings and Vertex Pharmaceuticals at 34.3. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and Vertex Pharmaceuticals's +23.5%.

Key facts

Bristol-Myers Squibb market value
$124.7B
Vertex Pharmaceuticals market value
$135.1B
Bristol-Myers Squibb P/E
13.5
Vertex Pharmaceuticals P/E
34.3
Bristol-Myers Squibb revenue
$48.2BFY to 2025-12-31
Vertex Pharmaceuticals revenue
$12BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Bristol-Myers Squibb vs Vertex Pharmaceuticals: every measure side by side
Measure Bristol-Myers Squibb Vertex Pharmaceuticals
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$124.7Blower$135.1Bhigher
Revenue$48.2Bhigher$12Blower
Earnings$7.1Bhigher$4Blower
Employees32,500higher6,400lower
Total assets$90Bhigher$25.6Blower
Valuation
P/E13.5lower34.3higher
P/S2.6lower11.3higher
P/B5.3lower6.5higher
Dividend yield4.00%higher0.00%lower
Profitability
Operating margin—34.8%
Balance sheet
Net assets$18.5Blower$18.7Bhigher
Total liabilities$71.5Bhigher$7Blower
Total debt$45.1B—
Cash on hand$10.2Bhigher$5.1Blower
Price change
Today-3.08%lower-0.91%higher
1 year+33.7%higher+23.5%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / Vertex Pharmaceuticals). Who owns BMY · Who owns VRTX

Further comparisons

Learn

Questions and answers

Which is bigger, Bristol-Myers Squibb or Vertex Pharmaceuticals?

By market value, Vertex Pharmaceuticals is the larger: $135.1B against $124.7B for Bristol-Myers Squibb. By revenue in its latest fiscal year, Bristol-Myers Squibb is the larger: $48.2B against $12B for Vertex Pharmaceuticals.

Which has the higher P/E ratio?

Vertex Pharmaceuticals: 34.3, against 13.5 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Bristol-Myers Squibb: 4.00%, against 0.00% for Vertex Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Bristol-Myers Squibb and Vertex Pharmaceuticals?

In their latest 13F filings, Tweedy, Browne team holds both.

Cite this page

Funkfolio, “Bristol-Myers Squibb vs Vertex Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/bmy-vs-vrtx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.